Preferred Label : Anti-SIRPa Monoclonal Antibody BI 770371;
NCIt synonyms : Anti-SIRPalpha Monoclonal Antibody BI 770371;
NCIt definition : An immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory
protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing
and antineoplastic activities. Upon administration, anti-SIRPa monoclonal antibody
BI 770371 targets and binds to SIRPa expressed on myeloid cells, including monocytes,
macrophages, dendritic cells (DCs), and neutrophils, thereby blocking the interaction
between SIRPa and its ligand cluster of differentiation 47 (CD47) expressed on tumor
cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated
inhibition of phagocytosis and the CD47/SIRPa-mediated suppression of the innate immune
response. This induces pro-phagocytic signaling and the specific phagocytosis of tumor
cells, and restores immune responses mediated by myeloid cells in the tumor microenvironment
(TME). SIRPa, an innate immune checkpoint receptor expressed primarily on myeloid
cells and neurons that is also known as tyrosine-protein phosphatase non-receptor
type substrate 1, mediates negative regulation of phagocytosis, mast cell activation
and DC activation. CD47, also known as integrin-associated protein (IAP), is a tumor-associated
antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed
on the surface of a variety of cancer cells. Expression of CD47, and its interaction
with SIRPa, leads to the inhibition of phagocytosis and the suppression of innate
immunity, which allows cancer cells to proliferate. BI 770371 binds to both the V1
and V2 variants of SIRPa.;
Molecule name : BI-770371; BI 770371;
NCI Metathesaurus CUI : CL1799107;
Origin ID : C190630;
UMLS CUI : C5783829;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
